CD8+ tumor-infiltrating lymphocytes (TILs) have been demonstrated to be important components of the TME and predict improved survival in several human malignancies, including breast cancer (17), ovarian cancer (18), and colorectal cancer (19). Here, CD8A is linked to neoplasm.